What drug is typically administered alongside Cyclophosphamide to reduce bladder toxicity?

The drug that is typically administered alongside Cyclophosphamide to reduce bladder toxicity is Mesna. Cyclophosphamide, an alkylating agent used in cancer treatment, can lead to a condition known as hemorrhagic cystitis, which is inflammation and bleeding in the bladder. Mesna acts as a uroprotectant by binding to the toxic metabolites of Cyclophosphamide in the urine, thereby preventing them from damaging the bladder lining. This protective effect makes Mesna an important adjunctive therapy to minimize the risk of bladder toxicity associated with the use of Cyclophosphamide.

Dexamethasone, Ondansetron, and Rituximab serve different purposes. Dexamethasone is a corticosteroid often used for its anti-inflammatory effects and to prevent nausea. Ondansetron is an antiemetic that prevents nausea and vomiting, frequently used in chemotherapy regimens but does not address bladder toxicity. Rituximab is a monoclonal antibody used primarily in certain types of lymphoma and autoimmune conditions but is not relevant to the prevention of bladder toxicity from Cyclophosphamide. Therefore, Mesna is the specific medication designed to counteract this particular side effect.